Drug Trial Radar · NCT07179575
Study of LW231 in Participants With Chronic Hepatitis B
Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
270
Planned (sponsor's estimate)
Start
Nov 11, 2025
Primary completion
Mar 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Shanghai Longwood Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ib/II, multicenter, randomized, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of LW231 in participants with chronic hepatitis B virus (HBV) infection. The trial will include multiple-dose regimens of LW231 and assess LW231 in combination with NUCs.
Conditions
- Chronic HBV Infection
Interventions
LW231Drug
LW231 tablets
LW231 placeboDrug
LW231 placebo tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in HBV DNA Viral Load AssayTime frame: 4 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China · Not yet recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.